Developing the 1st generation of oral biotherapeutics in Inflammatory Bowel Diseases

Within the European Commission’s Seventh Framework Program for Research (FP7), a consortium of nine partners from six different European countries collaborated on the SADEL project, which stands for “Scaffolds for Alternative DELivery”. Taking advantage of the Nanofitin protein scaffold, the SADEL project consisted of developing a blocking protein therapeutic deliverable orally for the treatment of Inflammatory Bowel Diseases. The clinically validated target chosen, TNF-alpha, is a cytokine considered a key regulator of immune cells and involved in systemic inflammation.

Objectives of such treatment are :

  • A better targeting of the inflammation site in the gut via oral administration
  • Decreasing systemic exposure and related side effects : reducing immunogenicity
  • Providing an efficient, safe and affordable drug, in a format that increases patient comfort and compliance to treatment

After the 60 months allotted to SADEL, the clinical development of the lead compound is pursued by Affilogic in partnership with the other members of the consortium.

SADEL was a project supported by the European Commission through the Seventh Framework Program (FP7).